Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Luteolin Nanocapsules Demonstrate Effective Anticancer Activity in Mouse Model

By BiotechDaily International staff writers
Posted on 23 Jan 2014
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Nanocapsules containing the natural antioxidant luteolin were found to be significantly more effective than natural luteolin in inhibiting growth of cancer cells both in culture and in a mouse xenograft model.

Luteolin is a flavone, a type of flavonoid, and, like all flavonoids, has a yellow crystalline appearance. Dietary sources include celery, green pepper, thyme, dandelion, chamomile tea, carrots, olive oil, peppermint, rosemary, navel oranges, and oregano. Luteolin reportedly acts as a monoamine transporter activator, and is one of the few chemicals demonstrated to possess this property. Experiments have suggested that luteolin may inhibit the development of some types of skin cancer.

In the current study, investigators at Emory University (Atlanta, GA, USA) formulated water-soluble polymer-encapsulated Nano-Luteolin from luteolin, and studied its anticancer activity against lung cancer and head and neck cancer. The low water solubility of luteolin, which hampers its use in treatment due to problems of low bioavailability, poor systemic delivery, and low efficacy, led the investigators to choose a nanocapsule format for their experiments.

Results published in the January 2014 issue of the journal Cancer Prevention Research revealed that like luteolin, Nano-Luteolin inhibited the growth of lung cancer cells (H292 cell line) and squamous cell carcinoma of head and neck (SCCHN) cells (Tu212 cell line). In vivo studies using a tumor xenograft mouse model demonstrated that Nano-Luteolin had a significant inhibitory effect on the tumor growth of SCCHN in comparison to luteolin.

"Our results suggest that nanoparticle delivery of naturally occurring dietary agents like luteolin has many advantages," said senior author Dr. Dong Moon Shin, professor of hematology and medical oncology at Emory University. "By using a high concentration of luteolin in the blood, we were better able to inhibit the growth of cancer cells."

Related Links:

Emory University


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.